Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Zydena, Levitra, Stendra), By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2022 - 2030

Report Overview

The global erectile dysfunction drugs market was valued at USD 2.30 billion in 2021 and is expected to expand at a compounded annual growth rate (CAGR) of 8.5% from 2022 to 2030. The increasing burden of lifestyle diseases and rising adoption of a sedentary lifestyle are responsible for the increasing incidence of Erectile Dysfunction (ED) worldwide. According to World Health Organization (WHO) report, around 15% of the male population were reported to be affected by erectile dysfunction every year which is projected to reach 320 million by 2025. Hence, increasing disease prevalence and rising demand for ED medicines are among the key factors driving the growth of the market. The COVID-19 pandemic had a positive impact on the sales of erectile dysfunction drugs owing to increased demand for products.

According to the University of Pittsburgh's School of Medicine, there was high growth in sales of erectile dysfunction drugs due to the government-imposed lockdown in 2020. Among all ED drugs, Cialis (Tadalafil) witnessed significant growth in sales in the U.S. Moreover, other factors such as easy access to ED drugs supported the growth of the market for erectile dysfunction drugs. Currently, various drugs are used to manage erectile dysfunction including, sildenafil (Revatio, Viagra), vardenafil (Levitra, Staxyn), tadalafil (Adcirca, Cialis), and avanafil (Stendra) among others.

Depending on the dose, generic sildenafil is frequently offered for a significantly lesser cost than Viagra, which typically costs around USD 70 per pill. Therefore, the availability of affordable medications may lead to higher prescription rates and market expansion. Considerably, the prevalence of ED is increasing with age due to comorbid conditions such as diabetes, obesity, and others. Men with medication, hormonal, neurological, and vascular etiologies are also at a high-risk development of disease.

A lifetime ED episode was experienced by around 35 -75% of male diabetic patients, according to the WHO. By 2021, there were 422 million diabetic patients living in low- and middle-income nations. However, the market growth could be hampered by a lack of healthcare infrastructure and manufacturing mistakes. For instance, Sun Pharmaceutical Industries Ltd. announced the recall of its generic drug Tadalafil in November 2021 as a result of a production fault. This recall could leave a small gap in the supply of ED generic drugs used to treat erectile dysfunction patients.

Product Insights

The viagra segment held the highest revenue share of 57.8% in 2021. At present, many companies are undertaking various strategic initiatives such as research collaboration, partnerships, and agreements with an aim to expand their business footprint. For instance, in January 2020, Pfizer, Inc., and Digital Men’s Clinic Roman signed a supply agreement to provide a generic version of Viagra to roman members. This supply agreement is expected to boost the growth of the segment.

The others segment is also expected to witness lucrative market growth over the forecast period owing to the large application base and availability of ED medicines, such as Helleva (lodenafil carbonate), Mvix (mirodenafil), and others that are also used to treat adult patients with erectile dysfunction. Increasing approval of over-the-counter ED products offers easy access to ED patients. For instance, in February 2022, Adamed was the first-ever polish company that received marketing authorization approval for Tadalafil MAXON from prescription to over-the-counter (OTC) category. Hence, the introduction of such products in the market may boost the utilization of ED drugs.

Regional Insights

North America dominated the erectile dysfunction drugs market and accounted for a revenue share of 51.7% in 2021 due to the high burden of disease, strong healthcare infrastructure, and approval of new products for treatment. In March 2022, Lupin received the U.S. FDA approval for its ANDA for sildenafil (10 mg/mL oral suspension) to market a generic equivalent to Revatio of Viatris Specialty LLC. The accessibility of affordable generic products may increase patient compliance, consequently, increasing the consumer base and revenue for the market.

In Asia Pacific, the market for erectile dysfunction drugs is expected to witness fast growth during the forecast period. The growth of the region is attributable to the entry of new products into the region. For instance, in May 2020, iX Biopharma announced the supply of Wafesil and Silcap through telemedicine in Australia for the treatment of an adult patient with erectile dysfunction.

Key Companies & Market Share Insights

Major players are adopting strategies such as mergers and acquisitions for regional expansion for a greater market share. For instance, the Spanish specialty pharmaceutical company Laboratorios Rubio S.A. sold the Rx brand Bandol to Aspargo Laboratories, Inc. in May 2022. Patients with ED disorders are treated with Bandol. Some of the prominent players in the erectile dysfunction drugs market include:

• Pfizer Inc.

• Eli Lilly and Company

• Teva Pharmaceutical Industries Ltd

• Sanofi

• Sun Pharmaceutical Industries Ltd

• Bayer AG

• Petros Pharmaceuticals, Inc.

• VIVUS, Inc.

• Auxilium Pharmaceuticals, Inc.

• Adamed

Erectile Dysfunction Drugs Market Report Scope

Global Erectile Dysfunction Drugs Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-markets from 2018 to 2030. For this study, Grand View Research has segmented the global erectile dysfunction drugs market report based on product and region:

• Product Outlook (Revenue, USD Million; 2018 - 2030)

  • Viagra

  • Cialis

  • Zydena

  • Levitra

  • Stendra

  • Others

• Regional Outlook (Revenue, USD Million; 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE